Application of IMDC criteria across first-line (1L) and second-line (2L) therapies in metastatic renal-cell carcinoma (mRCC): New and updated benchmarks of clinical outcomes.
Shaan Dudani(William Osler Health System), Daniel Yick Chin Heng(University of Calgary), Aaron R. Hansen(Princess Margaret Cancer Centre), Ziad Bakouny(Dana-Farber Cancer Institute), Benoit Beuselinck(Universitair Ziekenhuis Leuven), Connor Wells(Queen Mary University of London), Sumanta K. Pal(City of Hope), Toni K. Choueiri(Harvard University), Bernadett Szabados(Queen Mary University of London), Frede Donskov(Aarhus University Hospital), Chun Loo Gan(University of Calgary), Lori Wood(Dalhousie University), Christian Kollmannsberger(BC Cancer Agency), Nazlı Dizman(City Of Hope National Medical Center), Christina M. Canil(University of Ottawa), Thomas Powles(National Health Service), Sandy Srinivas(Stanford University), Neeraj Agarwal(University of Utah), Georg A. Bjarnason(Sunnybrook Health Science Centre), Elizabeth Liow(Peter MacCallum Cancer Centre)
Cited by 11
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.3k
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
|The Lancet|2016|2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k